Vanoxerine

Vanoxerine
Clinical data
Other names	GBR-12909; Boxeprazine; I-893
ATC code	None;
Pharmacokinetic data
Elimination half-life	6 hours approx
Identifiers
	IUPAC name 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine;
CAS Number	67469-69-6 ; HCl: 67469-78-7 ;
PubChem CID	3455;
DrugBank	DB03701 ; HCl: DBSALT001866;
ChemSpider	3337 ; HCl: 94684;
UNII	90X28IKH43; HCl: MWO1IP03EV ;
ChEBI	CHEBI:64089; HCl: CHEBI:64086;
ChEMBL	ChEMBL281594 ;
CompTox Dashboard (EPA)	DTXSID8045143 ;
Chemical and physical data
Formula	C28H32F2N2O
Molar mass	450.574 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1ccc(cc1)C(OCCN2CCN(CC2)CCCc3ccccc3)c4ccc(F)cc4;
	InChI InChI=1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2 ; Key:NAUWTFJOPJWYOT-UHFFFAOYSA-N ;

Vanoxerine is an investigational drug which is being evaluated for the treatment of heart arrhythmias and cocaine dependence. Vanoxerine is a piperazine derivative which has multiple pharmacological activities including acting as an dopamine reuptake inhibitor, serotonin transporter inhibitor, and as a blocker of the cardiac hERG repolarizing potassium channel (IKr).